چاپ صفحه |  صفحه نخست سامانه |  نویسندگان |  اطلاعات تفضیلی |  دانلود مقاله | دانشگاه علوم پزشکی تبریز |
| نویسنده | نفر چندم مقاله |
|---|---|
| افسانه فرجامی | اول |
| عنوان | متن |
|---|---|
| کلمات کلیدی | drug-antibody conjugates,' 'targeted therapy,' 'linker technology,' 'payload optimization,' and 'clinical trials |
| خلاصه مقاله | Drug-antibody conjugates (DACs) represent a revolutionary approach in targeted cancer therapy, merging the specificity of monoclonal antibodies with the potent cytotoxic properties of small-molecule drugs. This innovative strategy aims to minimize off-target effects while maximizing therapeutic efficacy. DACs consist of an antibody linked to a cytotoxic agent, allowing for selective delivery to cancer cells that express specific antigens. Recent advancements in this field have focused on improving linker technology, enhancing stability, and optimizing drug loading to ensure effective delivery and release of the cytotoxic agent within the tumor microenvironment. The rise of personalized medicine has further propelled the development of DACs, as they can be tailored to target unique tumor markers found in individual patients. Clinical trials have shown promising results, with several DACs receiving FDA approval, leading to improved survival rates and quality of life for patients with various malignancies. As research continues to uncover new targets and refine delivery mechanisms, DACs are poised to play a pivotal role in the future of oncology. |
| نام فایل | تاریخ درج فایل | اندازه فایل | دانلود |
|---|---|---|---|
| 20250302_130738.jpg | 1403/12/13 | 5709016 | دانلود |
| ADG.pptx | 1403/12/13 | 767334 | دانلود |
| 20250302_130618.jpg | 1403/12/13 | 5158058 | دانلود |
